Janus Henderson Group
GLUE icon

Janus Henderson Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Janus Henderson Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Buy
+685,926
New +$13.1M 0.01% 726
2023
Q4 		– Sell
-23,743
Closed -$114K – 2574
2023
Q3 		$114K Sell
23,743
-49
-0.2% -$315 ﹤0.01% 2496
2023
Q2 		$163K Buy
+23,792
New +$154K ﹤0.01% 2499

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group's GLUE Position: Q1 2026 in Review

Janus Henderson Group opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 685,926 shares worth $11.3M. The stake represents 0.01% of the portfolio and ranks #726 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in GLUE as recently as Q3 2023.

Janus Henderson Group first reported a position in GLUE in Q2 2023 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Janus Henderson Group held 685,926 shares of Monte Rosa Therapeutics worth $11.3M as of Q1 2026.
  • Monte Rosa Therapeutics was a new Janus Henderson Group position in Q1 2026.
  • Monte Rosa Therapeutics made up 0.01% of Janus Henderson Group's portfolio in Q1 2026, its #726 holding.
  • Janus Henderson Group first reported a position in Monte Rosa Therapeutics in Q2 2023 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.